IDEX Reports First Quarter Results; Delivers Q1 Operating Margin of 23.8 Percent and Record EPS of $1.44; Raises Full Year EPS Guidance
First Quarter 2019 Highlights
- Orders were up 4 percent overall and 6 percent organically
- Sales were up 2 percent overall and 4 percent organically
- Operating margin was 23.8 percent, up 120 bps
-
EPS was
$1.44 , up 12 percent
First Quarter 2019
Orders of
Sales of
Gross margin of 45.6 percent was up 40 basis points compared with the prior year period primarily due to price, productivity initiatives and volume leverage, partially offset by higher engineering investments across all three segments.
Operating income of
Provision for income taxes of
Net income was
Cash from operations of
The Company repurchased 370 thousand shares of common stock for
“Strong execution drove a solid start to the year for IDEX. First quarter organic orders and sales grew 6 and 4 percent, respectively. We generated $33 million of backlog during the quarter led by strong organic order growth of 10 percent in FMT and 9 percent in FSDP. Sales within most of our end markets remain strong, led by our industrial businesses. However, we continue to see softness in our agriculture and semiconductor markets, along with some volatility in our dispensing and MPT project-related businesses. Operating margin continues to be a great story, increasing 120 basis points with expansion across all three segments in the quarter. Overall, we delivered record first quarter EPS of $1.44, which was approximately 7 cents above the midpoint of our previous guidance, 2 cents of which was operational over achievement, with the remaining 5 cents due to a lower effective tax rate compared to our previous estimate. |
We continue to invest in resources for our best organic growth opportunities. These investments are paying dividends as evidenced by 11 consecutive quarters of organic order expansion and 9 consecutive quarters of organic sales growth. M&A remains a key priority for the Company and our balance sheet is in a very good position to support the right opportunities. In the meantime, we keep deploying capital in line with our framework, with $33 million returned to shareholders through dividends, and we repurchased 370 thousand shares of our stock for approximately $52 million. |
Taking into consideration our solid start to the year and favorability from tax, while keeping a cautious eye on the global economy, we are raising full year EPS guidance while maintaining our organic revenue projection. We now expect full year 2019 EPS of $5.70 to $5.85, with projected second quarter EPS of $1.47 to $1.50. Organic revenue growth expectation for both the second quarter and full year is 4 to 5 percent.” |
Andrew K. Silvernail |
Chairman and Chief Executive Officer |
First Quarter 2019 Segment Highlights
Fluid & Metering Technologies
-
Sales of
$242.5 million reflected a 4 percent increase compared to the first quarter of 2018 (+6 percent organic and -2 percent foreign currency translation). -
Operating income of
$71.9 million resulted in an operating margin of 29.6 percent, a 110 basis point increase compared to the adjusted prior year period primarily due to higher volume and productivity initiatives. -
EBITDA of
$77.3 million resulted in an EBITDA margin of 31.9 percent, a 100 basis point increase compared to the adjusted prior year period.
Health & Science Technologies
-
Sales of
$225.3 million reflected a 2 percent increase compared to the first quarter of 2018 (+3 percent organic, +1 percent acquisition and -2 percent foreign currency translation). -
Operating income of
$54.2 million resulted in an operating margin of 24.0 percent, a 10 basis point increase compared to the adjusted prior year period primarily due to lower amortization, partially offset by higher engineering investments. -
EBITDA of
$63.4 million resulted in an EBITDA margin of 28.1 percent, a 120 basis point decrease compared to the adjusted prior year period primarily due to business mix and a negative impact from foreign currency.
Fire & Safety/Diversified Products
-
Sales of
$156.2 million reflected a 2 percent decrease compared to the first quarter of 2018 (+1 percent organic and -3 percent foreign currency translation). -
Operating income of
$40.3 million resulted in an operating margin of 25.8 percent, a 90 basis point increase compared to the adjusted prior year period primarily due to productivity initiatives. -
EBITDA of
$43.3 million resulted in an EBITDA margin of 27.7 percent, a 190 basis point decrease compared to the adjusted prior year period primarily due to transaction gains included in Other (income) expense in the prior year period.
For the first quarter of 2019, Fluid & Metering Technologies contributed 39 percent of sales, 43 percent of operating income and 42 percent of EBITDA; Health & Science Technologies accounted for 36 percent of sales, 33 percent of operating income and 34 percent of EBITDA; and Fire & Safety/Diversified Products represented 25 percent of sales, 24 percent of operating income and 24 percent of EBITDA.
Non-U.S. GAAP Measures of Financial Performance
The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.
- Organic orders and sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
- Adjusted operating income is calculated as operating income plus restructuring expenses.
- Adjusted operating margin is calculated as adjusted operating income divided by net sales.
- Adjusted net income is calculated as net income plus restructuring expenses, net of the statutory tax expense or benefit.
- EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconciled EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
- Adjusted EBITDA is calculated as EBITDA plus restructuring expenses.
- Free cash flow is calculated as cash flow from operating activities less capital expenditures.
Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales |
||||||||||||||||
Three Months Ended | ||||||||||||||||
March 31, 2019 | ||||||||||||||||
FMT | HST | FSDP | IDEX | |||||||||||||
Change in net sales | 4 | % | 2 | % | (2 | )% | 2 | % | ||||||||
- Net impact from acquisitions | — | % | 1 | % | — | % | — | % | ||||||||
- Impact from FX | (2 | )% | (2 | )% | (3 | )% | (2 | )% | ||||||||
Change in organic net sales | 6 | % | 3 | % | 1 | % | 4 | % | ||||||||
Table 2: Reconciliations of Reported-to-Adjusted Operating Income and Margin (dollars in thousands) |
||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||
2019 | 2018 | |||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | |||||||||||||||||||||||||||||||||
Reported operating income (loss) | $ | 71,866 | $ | 54,154 | $ | 40,328 | $ | (18,566 | ) | $ | 147,782 | $ | 66,166 | $ | 51,806 | $ | 39,554 | $ | (20,843 | ) | $ | 136,683 | ||||||||||||||||||||
+ Restructuring expenses | — | — | — | — | — | 143 | 1,059 | 100 | 340 | 1,642 | ||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 71,866 | $ | 54,154 | $ | 40,328 | $ | (18,566 | ) | $ | 147,782 | $ | 66,309 | $ | 52,865 | $ | 39,654 | $ | (20,503 | ) | $ | 138,325 | ||||||||||||||||||||
Net sales (eliminations) | $ | 242,522 | $ | 225,290 | $ | 156,159 | $ | (1,740 | ) | $ | 622,231 | $ | 232,333 | $ | 221,075 | $ | 159,173 | $ | (257 | ) | $ | 612,324 | ||||||||||||||||||||
Reported operating margin | 29.6 | % | 24.0 | % | 25.8 | % | n/m | 23.8 | % | 28.5 | % | 23.4 | % | 24.8 | % | n/m | 22.3 | % | ||||||||||||||||||||||||
Adjusted operating margin | 29.6 | % | 24.0 | % | 25.8 | % | n/m | 23.8 | % | 28.5 | % | 23.9 | % | 24.9 | % | n/m | 22.6 | % | ||||||||||||||||||||||||
Table 3: Reconciliations of Reported-to-Adjusted Net Income and EPS(in thousands, except EPS) |
||||||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2019 | 2018 | |||||||||
Reported net income | $ | 110,268 | $ | 98,958 | ||||||
+ Restructuring expenses | — | 1,642 | ||||||||
+ Tax impact on restructuring expenses | — | (379 | ) | |||||||
Adjusted net income | $ | 110,268 | $ | 100,221 | ||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2019 | 2018 | |||||||||
Reported diluted EPS | $ | 1.44 | $ | 1.27 | ||||||
+ Restructuring expenses | — | 0.02 | ||||||||
+ Tax impact on restructuring expenses | — | — | ||||||||
Adjusted diluted EPS | $ | 1.44 | $ | 1.29 | ||||||
Diluted weighted average shares outstanding | 76,284 | 77,739 | ||||||||
Table 4: Reconciliations of EBITDA to Net Income(dollars in thousands) |
||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||
2019 |
2018 | |||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | |||||||||||||||||||||||||||||||||
Reported operating income (loss) | $ | 71,866 | $ | 54,154 | $ | 40,328 | $ | (18,566 | ) | $ | 147,782 | $ | 66,166 | $ | 51,806 | $ | 39,554 | $ | (20,843 | ) | $ | 136,683 | ||||||||||||||||||||
- Other (income) expense - net | 78 | 284 | 505 | (1,007 | ) | (140 | ) | 134 | (597 | ) | (3,621 | ) | (365 | ) | (4,449 | ) | ||||||||||||||||||||||||||
+ Depreciation and amortization | 5,506 | 9,507 | 3,462 | 184 | 18,659 | 5,694 | 11,389 | 3,774 | 197 | 21,054 | ||||||||||||||||||||||||||||||||
EBITDA | 77,294 | 63,377 | 43,285 | (17,375 | ) | 166,581 | 71,726 | 63,792 | 46,949 | (20,281 | ) | 162,186 | ||||||||||||||||||||||||||||||
- Interest expense | 10,921 | 11,000 | ||||||||||||||||||||||||||||||||||||||||
- Provision for income taxes | 26,733 | 31,174 | ||||||||||||||||||||||||||||||||||||||||
- Depreciation and amortization | 18,659 | 21,054 | ||||||||||||||||||||||||||||||||||||||||
Reported net income | $ | 110,268 | $ | 98,958 | ||||||||||||||||||||||||||||||||||||||
Net sales (eliminations) | $ | 242,522 | $ | 225,290 | $ | 156,159 | $ | (1,740 | ) | $ | 622,231 | $ | 232,333 | $ | 221,075 | $ | 159,173 | $ | (257 | ) | $ | 612,324 | ||||||||||||||||||||
Reported operating margin | 29.6 | % | 24.0 | % | 25.8 | % | n/m | 23.8 | % | 28.5 | % | 23.4 | % | 24.8 | % | n/m | 22.3 | % | ||||||||||||||||||||||||
EBITDA margin | 31.9 | % | 28.1 | % | 27.7 | % | n/m | 26.8 | % | 30.9 | % | 28.9 | % | 29.5 | % | n/m | 26.5 | % | ||||||||||||||||||||||||
Table 5: Reconciliations of EBITDA to Adjusted EBITDA(dollars in thousands) |
||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||
2019 | 2018 | |||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | |||||||||||||||||||||||||||||||||
EBITDA | $ | 77,294 | $ | 63,377 | $ | 43,285 | $ | (17,375 | ) | $ | 166,581 | $ | 71,726 | $ | 63,792 | $ | 46,949 | $ | (20,281 | ) | $ | 162,186 | ||||||||||||||||||||
+ Restructuring expenses | — | — | — | — | — | 143 | 1,059 | 100 | 340 | 1,642 | ||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 77,294 | $ | 63,377 | $ | 43,285 | $ | (17,375 | ) | $ | 166,581 | $ | 71,869 | $ | 64,851 | $ | 47,049 | $ | (19,941 | ) | $ | 163,828 | ||||||||||||||||||||
Adjusted EBITDA margin | 31.9 | % | 28.1 | % | 27.7 | % | n/m | 26.8 | % | 30.9 | % | 29.3 | % | 29.6 | % | n/m | 26.8 | % | ||||||||||||||||||||||||
Table 6: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow(in thousands) |
||||||||||||||
Three Months Ended | ||||||||||||||
March 31, | December 31, | |||||||||||||
2019 | 2018 | 2018 | ||||||||||||
Cash flows from operating activities | $ | 88,663 | $ | 71,729 | $ | 153,592 | ||||||||
- Capital expenditures | 12,875 | 10,009 | 16,233 | |||||||||||
Free cash flow | $ | 75,788 | $ | 61,720 | $ | 137,359 | ||||||||
Conference Call to be Broadcast over the Internet
IDEX will broadcast its first quarter earnings conference call over the
Internet on
Forward-Looking Statements
This news release contains “forward-looking” statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended. These statements may relate to, among other things, capital
expenditures, acquisitions, cost reductions, cash flow, revenues,
earnings, market conditions, global economies and operating
improvements, and are indicated by words or phrases such as
“anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,”
“should,” “could,” “will,” “management believes,” “the Company
believes,” “the Company intends,” and similar words or phrases. These
statements are subject to inherent uncertainties and risks that could
cause actual results to differ materially from those anticipated at the
date of this news release. The risks and uncertainties include, but are
not limited to, the following: economic and political consequences
resulting from terrorist attacks and wars; levels of industrial activity
and economic conditions in the U.S. and other countries around the
world; pricing pressures and other competitive factors and levels of
capital spending in certain industries, all of which could have a
material impact on order rates and the Company's results, particularly
in light of the low levels of order backlogs it typically maintains; the
Company's ability to make acquisitions and to integrate and operate
acquired businesses on a profitable basis; the relationship of the U.S.
dollar to other currencies and its impact on pricing and cost
competitiveness; political and economic conditions in foreign countries
in which the Company operates; developments with respect to trade policy
and tariffs; interest rates; capacity utilization and the effect this
has on costs; labor markets; market conditions and material costs; and
developments with respect to contingencies, such as litigation and
environmental matters. Additional factors that could cause actual
results to differ materially from those reflected in the forward-looking
statements include, but are not limited to, the risks discussed in the
“Risk Factors” section included in the Company’s most recent annual
report on Form 10-K filed with the
About IDEX
IDEX is a global fluidics leader serving high growth specialized
markets. We are best known for our expertise in highly engineered
fluidics systems and components, as well as for our expertise in fire
and safety products including the Jaws of Life® family of rescue and
recovery tools. Our products touch lives every day. Whether it’s a
life-saving rescue operation, dispensing fresh juice to a first grader
or fueling aircraft, IDEX is a leader in creating enabling technology
used in many of the most common everyday activities. For more
information, please visit www.idexcorp.com.
IDEX shares are traded on the
(Financial reports follow)
IDEX CORPORATION | ||||||||||
Condensed Consolidated Statements of Operations |
||||||||||
(in thousands except per share amounts) |
||||||||||
(unaudited) |
||||||||||
Three Months Ended | ||||||||||
March 31, | ||||||||||
2019 | 2018 | |||||||||
Net sales | $ | 622,231 | $ | 612,324 | ||||||
Cost of sales | 338,397 | 335,672 | ||||||||
Gross profit | 283,834 | 276,652 | ||||||||
Selling, general and administrative expenses | 136,052 | 138,327 | ||||||||
Restructuring expenses | — | 1,642 | ||||||||
Operating income | 147,782 | 136,683 | ||||||||
Other (income) expense - net | (140 | ) | (4,449 | ) | ||||||
Interest expense | 10,921 | 11,000 | ||||||||
Income before income taxes | 137,001 | 130,132 | ||||||||
Provision for income taxes | 26,733 | 31,174 | ||||||||
Net income | $ | 110,268 | $ | 98,958 | ||||||
Earnings per Common Share: | ||||||||||
Basic earnings per common share | $ | 1.46 | $ | 1.29 | ||||||
Diluted earnings per common share | $ | 1.44 | $ | 1.27 | ||||||
Share Data: | ||||||||||
Basic weighted average common shares outstanding | 75,442 | 76,419 | ||||||||
Diluted weighted average common shares outstanding | 76,284 | 77,739 | ||||||||
IDEX CORPORATION |
|||||||||
Condensed Consolidated Balance Sheets |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
March 31, 2019 | December 31, 2018 | ||||||||
Assets | |||||||||
Current assets | |||||||||
Cash and cash equivalents | $ | 456,130 | $ | 466,407 | |||||
Receivables - net | 333,782 | 312,192 | |||||||
Inventories | 298,327 | 279,995 | |||||||
Other current assets | 40,989 | 33,938 | |||||||
Total current assets | 1,129,228 | 1,092,532 | |||||||
Property, plant and equipment - net | 271,920 | 281,220 | |||||||
Goodwill and intangible assets | 2,067,148 | 2,081,282 | |||||||
Other noncurrent assets | 83,164 | 18,823 | |||||||
Total assets | $ | 3,551,460 | $ | 3,473,857 | |||||
Liabilities and shareholders' equity | |||||||||
Current liabilities | |||||||||
Trade accounts payable | $ | 160,594 | $ | 143,196 | |||||
Accrued expenses | 178,198 | 187,536 | |||||||
Short-term borrowings | 455 | 483 | |||||||
Dividends payable | — | 33,446 | |||||||
Total current liabilities | 339,247 | 364,661 | |||||||
Long-term borrowings | 848,437 | 848,335 | |||||||
Other noncurrent liabilities | 308,544 | 266,221 | |||||||
Total liabilities | 1,496,228 | 1,479,217 | |||||||
Shareholders' equity | 2,055,232 | 1,994,640 | |||||||
Total liabilities and shareholders' equity | $ | 3,551,460 | $ | 3,473,857 | |||||
IDEX CORPORATION | ||||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||||
(in thousands) |
||||||||||
(unaudited) |
||||||||||
Three Months Ended March 31, | ||||||||||
2019 | 2018 | |||||||||
Cash flows from operating activities | ||||||||||
Net income | $ | 110,268 | $ | 98,958 | ||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
Depreciation and amortization | 9,660 | 10,183 | ||||||||
Amortization of intangible assets | 8,999 | 10,871 | ||||||||
Amortization of debt issuance expenses | 335 | 332 | ||||||||
Share-based compensation expense | 7,560 | 7,652 | ||||||||
Deferred income taxes | 3,027 | (2,041 | ) | |||||||
Non-cash interest expense associated with forward starting swaps | 1,588 | 1,632 | ||||||||
Changes in (net of the effect from acquisitions): | ||||||||||
Receivables | (21,402 | ) | (30,816 | ) | ||||||
Inventories | (18,548 | ) | (21,116 | ) | ||||||
Other current assets | (7,119 | ) | 16,881 | |||||||
Trade accounts payable | 17,488 | 8,215 | ||||||||
Accrued expenses | (24,606 | ) | (27,273 | ) | ||||||
Other - net | 1,413 | (1,749 | ) | |||||||
Net cash flows provided by operating activities | 88,663 | 71,729 | ||||||||
Cash flows from investing activities | ||||||||||
Purchases of property, plant and equipment | (12,875 | ) | (10,009 | ) | ||||||
Proceeds from disposal of fixed assets | 629 | — | ||||||||
Other - net | (195 | ) | (184 | ) | ||||||
Net cash flows used in investing activities | (12,441 | ) | (10,193 | ) | ||||||
Cash flows from financing activities | ||||||||||
Dividends paid | (33,446 | ) | (28,945 | ) | ||||||
Proceeds from stock option exercises | 8,870 | 6,590 | ||||||||
Purchases of common stock | (50,797 | ) | — | |||||||
Shares surrendered for tax withholding | (11,479 | ) | (10,750 | ) | ||||||
Settlement of foreign exchange contracts | — | 6,618 | ||||||||
Other | (129 | ) | — | |||||||
Net cash flows used in financing activities | (86,981 | ) | (26,487 | ) | ||||||
Effect of exchange rate changes on cash and cash equivalents | 482 | 1,974 | ||||||||
Net increase (decrease) in cash | (10,277 | ) | 37,023 | |||||||
Cash and cash equivalents at beginning of year | 466,407 | 375,950 | ||||||||
Cash and cash equivalents at end of period | $ | 456,130 | $ | 412,973 | ||||||
IDEX CORPORATION | ||||||||||
Company and Segment Financial Information - Reported |
||||||||||
(dollars in thousands) |
||||||||||
(unaudited) |
||||||||||
Three Months Ended | ||||||||||
March 31, (a) |
||||||||||
2019 | 2018 | |||||||||
Fluid & Metering Technologies | ||||||||||
Net sales | $ | 242,522 | $ | 232,333 | ||||||
Operating income (b) | 71,866 | 66,166 | ||||||||
Operating margin | 29.6 | % | 28.5 | % | ||||||
EBITDA | $ | 77,294 | $ | 71,726 | ||||||
EBITDA margin | 31.9 | % | 30.9 | % | ||||||
Depreciation and amortization | $ | 5,506 | $ | 5,694 | ||||||
Capital expenditures | 3,230 | 4,674 | ||||||||
Health & Science Technologies | ||||||||||
Net sales | $ | 225,290 | $ | 221,075 | ||||||
Operating income (b) | 54,154 | 51,806 | ||||||||
Operating margin | 24.0 | % | 23.4 | % | ||||||
EBITDA | $ | 63,377 | $ | 63,792 | ||||||
EBITDA margin | 28.1 | % | 28.9 | % | ||||||
Depreciation and amortization | $ | 9,507 | $ | 11,389 | ||||||
Capital expenditures | 5,304 | 3,331 | ||||||||
Fire & Safety/Diversified Products | ||||||||||
Net sales | $ | 156,159 | $ | 159,173 | ||||||
Operating income (b) | 40,328 | 39,554 | ||||||||
Operating margin | 25.8 | % | 24.8 | % | ||||||
EBITDA | $ | 43,285 | $ | 46,949 | ||||||
EBITDA margin | 27.7 | % | 29.5 | % | ||||||
Depreciation and amortization | $ | 3,462 | $ | 3,774 | ||||||
Capital expenditures | 2,953 | 1,818 | ||||||||
Corporate Office and Eliminations | ||||||||||
Intersegment sales eliminations | $ | (1,740 | ) | $ | (257 | ) | ||||
Operating income (b) | (18,566 | ) | (20,843 | ) | ||||||
EBITDA | (17,375 | ) | (20,281 | ) | ||||||
Depreciation and amortization | 184 | 197 | ||||||||
Capital expenditures | 1,388 | 186 | ||||||||
Company | ||||||||||
Net sales | $ | 622,231 | $ | 612,324 | ||||||
Operating income | 147,782 | 136,683 | ||||||||
Operating margin | 23.8 | % | 22.3 | % | ||||||
EBITDA | $ | 166,581 | $ | 162,186 | ||||||
EBITDA margin | 26.8 | % | 26.5 | % | ||||||
Depreciation and amortization (c) | $ | 18,659 | $ | 21,054 | ||||||
Capital expenditures | 12,875 | 10,009 | ||||||||
IDEX CORPORATION |
||||||||||||
Company and Segment Financial Information - Adjusted |
||||||||||||
(dollars in thousands) |
||||||||||||
(unaudited) |
||||||||||||
Three Months Ended | ||||||||||||
March 31, (a) |
||||||||||||
2019 | 2018 | |||||||||||
Fluid & Metering Technologies | ||||||||||||
Net sales | $ | 242,522 | $ | 232,333 | ||||||||
Adjusted operating income (b) | 71,866 | 66,309 | ||||||||||
Adjusted operating margin | 29.6 | % | 28.5 | % | ||||||||
Adjusted EBITDA | $ | 77,294 | $ | 71,869 | ||||||||
Adjusted EBITDA margin | 31.9 | % | 30.9 | % | ||||||||
Depreciation and amortization | $ | 5,506 | $ | 5,694 | ||||||||
Capital expenditures | 3,230 | 4,674 | ||||||||||
Health & Science Technologies | ||||||||||||
Net sales | $ | 225,290 | $ | 221,075 | ||||||||
Adjusted operating income (b) | 54,154 | 52,865 | ||||||||||
Adjusted operating margin | 24.0 | % | 23.9 | % | ||||||||
Adjusted EBITDA | $ | 63,377 | $ | 64,851 | ||||||||
Adjusted EBITDA margin | 28.1 | % | 29.3 | % | ||||||||
Depreciation and amortization | $ | 9,507 | $ | 11,389 | ||||||||
Capital expenditures | 5,304 | 3,331 | ||||||||||
Fire & Safety/Diversified Products | ||||||||||||
Net sales | $ | 156,159 | $ | 159,173 | ||||||||
Adjusted operating income (b) | 40,328 | 39,654 | ||||||||||
Adjusted operating margin | 25.8 | % | 24.9 | % | ||||||||
Adjusted EBITDA | $ | 43,285 | $ | 47,049 | ||||||||
Adjusted EBITDA margin | 27.7 | % | 29.6 | % | ||||||||
Depreciation and amortization | $ | 3,462 | $ | 3,774 | ||||||||
Capital expenditures | 2,953 | 1,818 | ||||||||||
Corporate Office and Eliminations | ||||||||||||
Intersegment sales eliminations | $ | (1,740 | ) | $ | (257 | ) | ||||||
Adjusted operating income (b) | (18,566 | ) | (20,503 | ) | ||||||||
Adjusted EBITDA | (17,375 | ) | (19,941 | ) | ||||||||
Depreciation and amortization | 184 | 197 | ||||||||||
Capital expenditures | 1,388 | 186 | ||||||||||
Company | ||||||||||||
Net sales | $ | 622,231 | $ | 612,324 | ||||||||
Adjusted operating income | 147,782 | 138,325 | ||||||||||
Adjusted operating margin | 23.8 | % | 22.6 | % | ||||||||
Adjusted EBITDA | $ | 166,581 | $ | 163,828 | ||||||||
Adjusted EBITDA margin | 26.8 | % | 26.8 | % | ||||||||
Depreciation and amortization (c) | $ | 18,659 | $ | 21,054 | ||||||||
Capital expenditures | 12,875 | 10,009 | ||||||||||
(a) | Three month data includes the results of Finger Lakes Instrumentation (July 2018) in the Health & Science Technologies segment from the date of acquisition. | |||||||||||
(b) | Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations. | |||||||||||
(c) | Depreciation and amortization excludes amortization of debt issuance costs. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005784/en/
Source:
Investor Contact:
William K. Grogan
Senior Vice
President and Chief Financial Officer
(847) 498-7070